2364. Evaluation of Renal Function Changes in Patients With Prolonged Telavancin Therapy (>21 Days): Results From the Telavancin Observational Use Registry (TOUR™)

BACKGROUND: Telavancin (TLV) is a lipoglycopeptide antibacterial active against a wide range of Gram-positive organisms, including methicillin-susceptible and methicillin-resistant Staphylococcus aureus. New onset or worsening renal impairment was observed in phase 3 clinical trials. This analysis w...

Descripción completa

Detalles Bibliográficos
Autores principales: Hassoun, Ali, Sundareshan, Vidya, Lacy, Melinda, Barnes, Chris, Castaneda-Ruiz, Bibiana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255214/
http://dx.doi.org/10.1093/ofid/ofy210.2017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255214/
http://dx.doi.org/10.1093/ofid/ofy210.2017

Ejemplares similares